DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

Rhea-AI Summary

DiaMedica Therapeutics Inc. will release its first quarter 2023 financial results on May 15th and host a conference call on May 16th to discuss the results.

Positive

• DiaMedica Therapeutics Inc. will release its first quarter 2023 financial results on May 15th, which could provide important insights for investors.

Negative

• None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15^th. DiaMedica will host a live conference call on Tuesday, May 16^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:

Date:	Tuesday, May 16, 2023
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://app.webinar.net/r4298p1YBXV
Dial In:	(877) 550-1858
Conference ID:	2125#

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 23, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005416/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics release its first quarter 2023 financial results?

DiaMedica Therapeutics will release its first quarter 2023 financial results on May 15th.

When is the conference call to discuss the financial results?

The conference call to discuss the financial results will be held on May 16th.

Where can I access the webcast of the conference call?

You can access the webcast of the conference call at https://app.webinar.net/r4298p1YBXV.

What is the dial-in number for the conference call?

The dial-in number for the conference call is (877) 550-1858.

What is the conference ID for the call?

The conference ID for the call is 2125#.

Will there be a replay of the conference call available?

Yes, a telephonic replay of the conference call will be available until May 23, 2023, by dialing (800) 645-7964 and entering the replay passcode: 2125#.